hepatocytes (8, 89, 113) . Pressure overload, nutrient starvation, exercise, and acute IPC 135 upregulate Sirt1 (5, 39) in the heart. Nucleocytoplasmic shuttling may also regulate the 136 function of Sirt1, since Sirt1 has both nuclear localization and nuclear export signals, 137 which are regulated via phosphorylation by PI3K in C2C12 cells (132) . Sirt1 is thought 138 to localize in both the cytoplasm and the nucleus at baseline and move to the nucleus in 139 response to stress in the heart (132). 140
Only a few proteins have been demonstrated to be directly deacetylated and 141 functionally regulated by Sirt1. These include FoxOs, p53, and polyadenosine 142 diphosphate (ADP)-ribose polymerase (PARP) 1 (5, 102, 111, 131) . FoxO, a mammalian 143 homolog of Daf16, which is involved in DNA repair, cell cycle, cell death/survival, and 144 regulation of reactive oxygen species (ROS), is both positively and negatively regulated 145 by Sirt1. Sirt1 deacetylates and activates FoxOs to upregulate expression of 146 anti-oxidants, including MnSOD, catalase, and thioredoxin1, and anti-apoptotic factors, 147
like in cardiomyocytes (14, 20, 39) . Sirt1 also activates Akt/PI3K signaling, 148 leading to enhancement of the cardiac hypertrophic response (125). 149
As described above, the regulatory mechanisms and targets of Sirt1 have been 150 well investigated. However, less is known regarding those of other sirtuin family 151
proteins. Several studies have raised the possibility that sirtuin proteins are regulated 152 by a common pathway and that the sirtuin proteins regulate one another. AMPK 153 increased expression of Sirt1, Sirt2, Sirt3, and Sirt6, whereas Sirt5 mRNA was 154 downregulated, in mouse hepatocytes (15). Sirt1 can bind and activate the Sirt6 155 promoter, which may amplify the response to stress in hepatocytes (50). Recently, fatty 156 acyl modification of TNF-α was also found to be regulated by Sirt6 in MEF cells (46).
(FFA) as a substrate for adenosine triphosphate (ATP) production under physiological 170 conditions. In failing hearts, the preferred substrate switches from FFA to glucose to 171 produce more ATP per molecule of oxygen consumed. However, the advanced failing 172 heart develops insulin resistance in the myocardium and undergoes a decline in glucose 173 utilization, limiting ATP production (94). 174 PGC-1α, a transcriptional co-activator of nuclear receptors, including 175 peroxisome proliferator-activated receptor α (PPARα) and estrogen-related receptor 176 (ERR) α, is a master regulator of metabolism and mitochondrial biogenesis. Sirt1 177 directly binds to PGC-1α and deacetylates it in 293T cells (116) and PC12 cells (93) . 178
Sirt1 stimulates the ability of PGC-1α to co-activate HNF4α, thereby positively 179 regulating gluconeogenic genes in response to pyruvate in hepatic cells (116) . In the 180 same cell type, Sirt1 also enhances the ability of PGC-1α to inhibit glycolytic genes in 181 response to pyruvate (116) . In PC12 cells, wild type Sirt1, but not a Sirt1 mutant that 182 cannot interact with PGC-1α, negatively regulates the transcriptional activity of 183 . Thus, the functional consequences of PGC-1α deacetylation appear 184 diverse and cell type-or transcription factor-dependent. Furthermore, Krishnan J et al. 185 demonstrated that Sirt2, but not Sirt1, affects fatty acid oxidation in adipocytes and 186 that knockdown of PGC-1α cancels the effect of overexpression of Sirt2 upon fatty acid 187 oxidation (54). Thus, the availability of other family members also contributes to the net 188 effect of sirtuins upon PGC-1α. Systemic deletion of Sirt1 in mice induces the 189 development of dilated cardiomyopathy, which is accompanied by mitochondrial 190 dysfunction (104). However, Sirt1 is upregulated in the failing heart and contributes to 191 downregulation of genes involved in mitochondrial function that are regulated by ERRs 192 (97) . Thus, the effect of Sirt1 upon mitochondrial function and metabolism in the heart 193 is also complex and possibly dose-dependent. include Mn-superoxide dismutase (SOD), NADH dehydrogenase 1α subcomplex 9, and 213 succinate dehydrogenase complex subunit A (4, 133), suggesting that Sirt3 is closely 214 tied to energy metabolism. Sirt3 also deacetylates and activates acetyl-CoA synthetase 215 2, a key enzyme in acetyl-CoA production, and long-chain acyl co-enzyme A 216 dehydrogenase (LCAD), a key enzyme of fatty acid oxidation, in the liver (36). Knockout 217 of Sirt3 exhibited a 50% decrease in basal ATP content in the heart (4). Together, these 218 data indicate that Sirt3 increases energy production by activating the mitochondrial 219 electron transport chain (ETC) and upregulating fatty acid oxidation. 220
Reduced Sirt2 function directly diminishes deacetylation of PGC-1α and 221 expression of β-oxidation and mitochondrial genes in adipocytes (54). Ramakrishnan et 222 al. reported that, although Sirt2 interacted with Akt and activated it in 223 insulin-responsive cell lines, they could not detect acetylation of Akt (112). So far, the 224 role of Sirt2 in mitochondrial function and energy metabolism in the heart remains 225 unclear. Inhibition of Sirt4 increases fatty acid oxidation in liver and mitochondrial 226 function in muscle. Sirt4 also inhibits glutamate dehydrogenase and impairs insulin 227 secretion in pancreatic β-cells (32). Overexpression of Sirt5 increases oxygen 228 consumption and ATP synthesis in human hepatocellular carcinoma cells, but is not 229 9 hemodynamic overload, such as pressure or volume overload, and is characterized by 242 enhanced protein synthesis and sarcomeric reorganization, leading to increased 243 cardiomyocyte size. Hypertrophic growth initially reduces wall stress, maintains 244 cardiac function and serves as a compensatory response to hypertrophic stimuli, but it 245 eventually initiates the development of cardiac remodeling and heart failure. 246
Pathological hypertrophy is recognized as a strong independent factor in heart failure. 247
Reversible modification of the acetylation status of proteins by HATs and HDACs 248 critically regulates the activity of signaling molecules mediating cardiac hypertrophy 249 (34). Class I HDACs, including HDAC1, 2, 3, and 8, positively regulate cardiac 250 hypertrophy, whereas class II HDACs, including HDAC4, 5, 7, and 9, negatively 251 regulate cardiac hypertrophy (152). Class II HDACs are expressed only in 252 nonproliferative cells, including cardiomyocytes. The export of class II HDACs from the 253 nucleus to the cytosol in the heart directly induces transcription of nuclear factor of 254 activated T cell (NFAT) and myocyte enhancer factor 2 (MEF2), master positive 255 regulators of cardiac hypertrophy (9). Class II HDACs are regulated by several forms of 256 post-translational modification, including phosphorylation, ubiquitination, and 257 sumoylation (9, 52, 108). Recently, it was shown that thioredoxin1 (Trx1) regulates the 258 nucleocyotplasmic shuttling of HDAC4 through a redox-dependent mechanism (3). By 259 forming a multiprotein complex with Trx1-binding protein-2 and DnaJb5, Trx1 reduces 260 HDAC4 at C667 and C669, which are easily oxidized to form a disulfide bond in 261 response to hypertrophic stimuli. The redox status of these cysteines plays a critical role 262 in the localization of HDAC4, thereby regulating cardiac hypertrophy (3). 263
Sirtuins have been demonstrated to be involved in cardiac hypertrophy, 264 although their effects vary depending upon experimental conditions. Resveratrol 265 attenuates the phenylephrine-induced hypertrophic response in cardiomyocytes and 266 pressure-overload-induced cardiac hypertrophy. Pharmacological inhibition of Sirt1 267 (with nicotinamide (NAM) or sirtinol) decreases, whereas overexpression of Sirt1 268 increases the size of cardiomyocytes (6). Overexpression of Sirt1 attenuates 269 endothelin-1-induced cardiomyocyte hypertrophy in vitro via degradation of H2A.z.
270
Upregulation and activation of Sirt1 induced by phenylephrine (an α-adrenergic 271 agonist) is blocked by inhibition or downregulation of AMP-activated Protein Kinase 272 (AMPK), leading to attenuated cardiac hypertrophy. Phenylephrine-induced 273 hypertrophy in cardiomyocytes is attenuated by resveratrol and overexpression of Sirt1. 274
This anti-hypertrophic effect is canceled by downregulation of PPARα. On the other 275 hand, pressure overload co-upregulates Sirt1 and PPARα in the heart, which 276 coordinately suppress genes that are regulated by ERRs, thereby leading to the 277 development of cardiac hypertrophy and heart failure ( Figure 1 ) (97). Importantly, 278 haploinsufficiency of PPARα and Sirt1 attenuates cardiac hypertrophy in response to 279 pressure overload (97). Interestingly, although low (2.5-fold) to moderate (7.5-fold) levels 280 of overexpression of Sirt1 in the heart attenuate age-dependent cardiac hypertrophy, a 281 high level (12.5-fold) of Sirt1 increases it (5). Thus, the effect of Sirt1 upon cardiac 282 hypertrophy may be affected by a balance of interaction with other factors, such as 283 PPARα, or severity and type of stress. In addition, cardiac hypertrophy is a 284 multifactorial disease and may also be affected by angiogenesis, apoptosis, and fibrosis. The role of Sirt6 in cardiac hypertrophy has been investigated using loss-and 307 gain-of-function models (127). Sirt6 knockout mice exhibited cardiac hypertrophy and 308 heart failure, whereas overexpression of Sirt6 attenuated cardiac hypertrophy, 309 indicating that Sirt6 negatively regulates cardiac hypertrophy. Unlike Sirt1 and Sirt3,activation in insulin-and growth-factor-responsive cells, the role of Sirt2 in cardiac 314 hypertrophy is still unclear. Likewise, although Sirt4, Sirt5, and Sirt7, like Sirt1 and 315
Sirt3, appear to be protective against stress in the heart, there has been no report thus 316 far regarding the role of these proteins in cardiac hypertrophy. 317 318 4. Role of sirtuins in cardiac function and heart failure 319
Heart failure represents a condition in which cardiac output is insufficient to 320 meet the needs of peripheral organs. Heart failure is caused by almost all cardiac diseases, 321 including myocardial infarction, hypertension, valvular heart disease, cardiomyopathy, 322 and arrythmia, and is one of the leading causes of death worldwide. These cardiac 323 diseases frequently provoke left ventricular (LV) dilatation and hypertrophy, which are 324 collectively referred to as ventricular remodeling and contribute to the development of 325 depressed cardiac performance (101). Pathophysiological LV remodeling is 326 characterized by cardiomyocyte hypertrophy and death and interstitial fibrosis. The 327 mechanisms mediating these processes are triggered by hemodynamic stress, as well as 328 by the activation of neurohumoral factors, including the autonomic nervous system and 329 the renin-angiotensin system, and ROS. Given the effects of sirtuins in cardiac 330 hypertrophy, cell death/survival, and oxidative stress, sirtuins appear to be closely 331 involved in cardiac remodeling and heart failure. repressing the activity of GATA4, NFAT, eukaryotic initiation factor 4E (eIF4E), and S6 375 ribosomal protein (S6P) (116). 376
The expression level of Sirt6 is decreased in the failing heart in humans, and a 377 recent study demonstrated the beneficial role of Sirt6 in heart failure (127). Deletion of 378
Sirt6 induces cardiac hypertrophy and heart failure in mice, whereas overexpression of 379 Sirt6 attenuates development of cardiac hypertrophy in response to hypertrophic 380 stimuli. Sirt6 binds to and suppresses the promoters of genes involved in IGF-signaling 381 by interacting with c-Jun and deacetylating Histone H3 at K9, thereby inhibiting the 382 abnormal activation of IGF-Akt signaling implicated in the progression of heart failure. 383
Another important aspect of cardiac remodeling is angiogenesis. Dissociation 384 between angiogenesis and cardiac muscle growth triggers the development ofpathological hypertrophy and eventually causes heart failure (123). Thus, the effect of 386 sirtuins on vascular phenotype is also implicated in the pathogenesis of heart failure. 387
Sirt1 plays a critical role in sprouting angiogenesis during vascular development, and 388
Sirt1 in endothelial cells impairs the formation of new blood vessels in ischemic tissues 389 (107). Sirt1 interacts with and deacetylates FoxO1, which plays an essential role in the 390 negative regulation of blood vessel development, in HUVECs (107). Inhibition of Sirt1 391 blocks NO production and endothelium-dependent vasodilation (79), and resveratrol 392 activates eNOS and increases NO production, thereby protecting the heart from 393 ischemia/reperfusion (I/R) injury (42). In addition, resveratrol induces angiogenesis in a 394 myocardial infarction model (28). The induction of angiogenesis by Sirt1 may be 395 mediated by p53. p53 acts as an anti-angiogenetic factor because it inhibits the activity 396 of hypoxia-inducible factor-1 (HIF-1), which regulates hypoxic adaptation genes such as 397 VEGF, and Sirt1 deacetylates p53 and reduces its transcriptional activity in 398 cardiomyocytes (6). Supporting this speculation, endothelial-cell-specific ablation of 399
Sirt1 induces impairment of angiogenesis and diastolic dysfunction in the heart through 400 downregulation of VEGF receptors FLT 1 and FLK 1 (70). Sirt3 also appears to be 401 involved in angiogenesis in the heart. In fact, Sirt3 induces bone-marrow-cell 402
(BMC)-induced VEGF expression and angiogenesis post-myocardial infarction (151). 403
However, less is known regarding the involvement of Sirt3 in angiogenesis. In addition, 404 thus far, there have been no reports of a role for other sirtuin family proteins. 405 Ca 2+ homeostasis is also closely involved in the pathogenesis of heart failure. 406 SERCA2a-regulated Ca 2+ uptake into the sarcoplasmic reticulum is decreased in the 407 failing heart (7). Resveratrol improves SERCA2a promoter activity under high glucose 408 conditions in a Sirt1-dependent manner. However, the role of sirtuins in Ca 2+ regulation 409 in cardiomyocytes remains unclear. 410 411
Sirtuins and ischemia/reperfusion injury 412
I/R is a major cause of myocardial injury and a life-threatening event in the 413 clinical setting. Ischemia or hypoxia in the heart induces a rapid decrease in ATP 414 content in cardiomyocytes. In order to survive under these conditions, cardiomyocytes 415 switch their metabolism from fatty acid oxidation (aerobic mechanism) to glycolysis 416 (anaerobic). Prolonged ischemia induces cytochrome c release from mitochondria and 417 triggers apoptosis in cardiomyocytes. Mitochondrial permeability transition pore 418 (mPTP) opening is followed by increases in Ca 2+ overload, depletion of ATP, and 419 decreases in the intracellular pH, eventually causing necrosis in cardiomyocytes (71).and washes out toxic substances derived from necrotic cells, the rapid recovery of the 422 oxygen supply and extracellular pH causes further ROS production and Ca 2+ overload, 423 leading to reperfusion injury such as necrosis and apoptosis (24). If cardiomyocytes 424 survive after reperfusion, both oxidative stress and endoplasmic reticulum stress can 425 induce cellular malfunction. Thus, I/R induces irreversible damage to cardiac muscle 426 and leads to cardiac remodeling and heart failure characterized by dilation of the 427 ventricle and reduced contractility. 428
Considering the favorable effects of Sirt1 in energy metabolism and stress 429 resistance in the heart, Sirt1 can be expected to have a beneficial effect on I/R injury. 430
Indeed, alteration of the expression level of Sirt1 in cardiomyocytes has been 431 demonstrated to affect myocardial injury and cardiac function after I/R. After I/R, 432 expression of Sirt1 is decreased in the heart, and cardiac-specific deletion of Sirt1 433 increases apoptosis and myocardial injury during I/R (39). Conversely, overexpression of 434 cardiac-specific Sirt1 decreases apoptosis and infarct size and improves functional 435 recovery after I/R by upregulating cardioprotective molecules, including MnSOD, Trx1, 436
and Bcl-xL, and downregulating proapoptotic molecules, including Bax (Figure 1) (39) . 437
NF-κB, isocitrate dehydrogenase (IDH), glyceraldehyde-3-phosphate dehydrogenase 438 (GAPDH), and eNOS have been proposed as functional targets of IPC-induced Sirt1 (88). 439
On the other hand, resveratrol-induced Sirt1 activation attenuates cardiac I/R injury 440 via a reduction in p38 and JNK phosphorylation and an increase in ERK 441 phosphorylation, which are regulated by Akt/ASK1 signaling (13). 442 Whereas Sirt1 is upregulated by aging, oxidative stress, and heart failure, it is 443 downregulated by I/R (39), suggesting that regulation of Sirt1 is stimulus-specific. The 444 precise mechanism by which a given stress upregulates/downregulates Sirt1 and 445 controls the function of specific substrates is not well understood. Sirt1 deacetylase 446 activity is regulated in an NAD + -dependent manner. Administration of NMN increases 447 NAD + in the heart and attenuates myocardial I/R injury, accompanied by a decrease in 448 acetylation of FoxO1. However, this effect is not observed in Sirt1 knockout mice (147). 449
The protective effects of IPC and CR, which upregulate Nampt, the rate-limiting 450 enzyme for NAD + synthesis, are abolished by Sirt1 knockout, suggesting that the 451 Nampt-Sirt1 axis plays a pivotal role in mediating the protective effects of IPC and CR 452 in I/R injury (147). Prolonged CR enhances myocardial ischemic tolerance by increasing 453 nuclear Sirt1 in a nitric-oxide-dependent manner in middle-aged mice (122). In addition, cardiomyocytes and the heart (5). Cardiac-specific overexpression of Sirt1 induces an 506 increase in protein expression of catalase after exposure to paraquat (5). 507
Overexpression of Sirt1 also upregulates MnSOD and Trx1 and attenuates oxidative 508 stress during cardiac I/R (39). However, it should be noted that a high level of Sirt1 509 expression in the heart conversely induces oxidative stress through dysregulation of 510 mitochondrial biogenesis and function at baseline in mice (5). Thus, it appears that the 511 cardiac effect of Sirt1 against oxidative stress is dose-dependent. Furthermore, the 512 activity of Sirt1 is controlled by the ratio of NAD + to NADH, an intracellular 513 redox-sensitive mechanism, in skeletal muscle (29). An intimate relationship between 514
Sirt1 and oxidative stress may affect cell survival in some pathological situations. 515
Sirt3 also increases antioxidant capacity by upregulating MnSOD through 516 FoxO3a in the heart (124) (Figure 2 ). In addition, Sirt3 increases the ROS scavenging 517 activity of MnSOD by deacetylating it at K53/K68 and K122 in mouse embryonic 518 fibroblasts (110, 133) . Other antioxidants are regulated by Sirt3 as well, probably in an 519 indirect manner. Sirt3 is thought to increase NADPH production by deacetylating and 520 activating isocitrate dehydrogenase 2 (IDH2) and glutamate dehydrogenase, which in 521 turn enhances the conversion of oxidized glutathione to reduced glutathione (64). Sirt3 522 inhibits ROS-induced Ras-PI3K-Akt signaling by suppressing mitochondrial ROS 523 production (124). 524
Recently, the biological function of Sirt2 in oxidative stress was reported. 525
Oxidative stress, such as due to increased hydrogen peroxide levels, increases 526 expression of Sirt2 in NIH3T3 cells, and Sirt2 lowers the ROS level by upregulatingmacrophage-like cell line. Likewise, PEP-1-SIRT2 decreases cellular levels of ROS, 530 accompanied by elevation of MnSOD, catalase, and GPx expression. The Sirt2-mediated 531 deacetylation and activation of Glucose-6-phosphate dehydrogenase (G6PD) stimulates 532 the pentose phosphate pathway (PPP) to supply cytosolic NADPH to counteract 533 oxidative damage and protect mouse erythrocytes (142). On the other hand, a study 534 using a cDNA microarray demonstrated that Sirt2 knockdown in primary HUVECs 535 causes global gene expression changes in response to oxidative stress, most of which are 536 not altered by Sirt1 knockdown. Importantly, pharmacological blockade of Sirt2 537 attenuates oxidative stress-induced endothelial cell injury (62). Thus, the effects of 538
Sirt2 are thought to depend on the type of cell and stimulation. Thus far, no intensive 539 study regarding Sirt2 and oxidative stress in the heart has been reported. 540
Sirt5 is known to be downregulated by oxidative stress in cardiomyocytes and 541 to act as a safeguard against ROS by reducing ROS-induced cell death (61). However, it 542 is still unclear whether and how Sirt5 regulates the ROS level in the heart. Sirt6 543 physically interacts with PARP1 and increases PARP1 poly-ADP-ribosylase activity via 544 mono-ADP-ribosylation of PARP1 at K521, thereby enhancing DNA double-strand 545 break repair under conditions of oxidative stress (74). Sirt7-deficient cardiomyocytes 546 exhibit increases in apoptosis under basal conditions and a significant increase in 547 sensitivity to oxidative stress (137). These findings suggest that Sirt5, Sirt6, and Sirt7 548 play protective roles against ROS-induced injury, consistent with their beneficial effects 549 under other stress conditions. Less is known, however, regarding the role of Sirt4 in 550 oxidative stress. 551 NADPH oxidase (Nox) proteins, which are dedicated producers of O2 -and/or 552 H2O2, were recently recognized to be major sources of ROS in cells. Thus far, seven 553 members of the Nox family of proteins (Nox1-5, Duox1 and Duox2) have been identified.attenuated by resveratrol. In addition, Sirt1 inhibition-induced endothelial dysfunction 566 is inhibited by treatment with apocynin or superoxide dismutase in rat aortas (150) . 567
These data suggest that the protective effect of Sirt1 against oxidative stress in the 568 heart may be partly due to suppression of Nox4 activity, since Nox4 is a major Nox 569 isoform in cardiomyocytes (2). Furthermore, the activities of sirtuins are 570 and cleavage of caspase-3 (6). Sirt1 has been reported to deacetylate p53 and FoxO, 585 thereby regulating transcription and apoptosis in mouse and human cells (17, 65, 83, 586 138). In the heart, Sirt1 positively regulates expression of the anti-apoptotic protein 587
Bcl-xL, whereas it negatively regulates pro-apoptotic proteins Bax and cleaved 588 caspase-3 through activation of FoxO (39). Importantly, inhibition of the activity of Sirt1, 589 but not other HDACs, increases the acetylation and transcriptional activity of p53 in 590 cardiomyocytes, suggesting that Sirt1 plays a more critical role in regulating p53 than 591 other classes of HDACs in cardiomyocytes. These data strongly suggest that Sirt1 592 exerts protective effects in the heart. The deacetylase activity of Sirt1 critically depends 593 upon the nuclear NAD + content, which is consumed when DNA strand breaks activate 594
The mPTP is found in the mitochondrial inner membrane, and passes small 602 molecules non-selectively in response to stimuli. mPTP opening is a hallmark of 603 mitochondrial dysfunction and causeses depletion of ATP and release of pro-apoptotic 604 factors, eventually leading to apoptosis and necrosis of cardiomyocytes (117). mPTP 605 opening is closely related to apoptosis/necrosis and the aging process. A recent study 606
showed that Sirt3, a mitochondrial sirtuin protein, deacetylates cyclophilin D, a 607 component of the mPTP, and inhibits mPTP opening, thereby reducing oxidative stress 608 and slowing down cardiac aging in the heart (Figure 2) . Thus, regulation of the mPTP 609 by Sirt3 is an important pathway for the cardioprotective effect of Sirt3. 610 Sirt1 attenuates age-dependent cardiac phenotypes, whereas animals with a high level 631 of Sirt1 (12.5-fold overexpression of Sirt1) develop heart failure spontaneously (5). This 632 may be due to the consumption of NAD + by Sirt1. Because NAD + is neccesary for the 633 mitochondrial ETC and ATP production, a decrease in NAD + could cause a deficiency in 634 ATP content and cellular malfunction, thereby leading to cell death. PGC-1α, a key 635 regulator of fatty acid oxidation, is decreased in aging hearts, and Sirt1 regulatesimproving energy metabolism. 638
As a mechanism mediating lifespan extension, the 'hormesis hypothesis', in 639 which accumulated stress resistance conferred by chronic nonlethal stress leads to 640 lifespan extension, is currently well accepted. This hypothesis allows for speculation 641 that stimulation of Sirt1 by low-grade stress, such as CR or repetitive ischemia, may 642 partly mediate the beneficial effect of preconditioning. 643 644
Sirtuins and autophagy 645
Autophagy is a mechanism of degradation of cytosolic proteins and organelles 646 involving sequestration into double-membrane vesicles (autophagosomes) and 647 subsequent fusion of the autophagosomes with lysosomes for degradation. Autophagy is 648 activated in response to several kinds of stress and promotes cell survival by removing 649 damaged organelles and preventing activation of the apoptotic machinery. In the heart, 650 autophagy acts as a mechanism for quality control of proteins, and is implicated in 651 several important pathophysiologies, including cardiac hypertrophy (21), 652 cardiomyopathies (95), heart failure (90), and ischemic heart disease (33). suggest that Sirt1 is a key regulator of autophagy in the heart and that, in general, 689 enhanced autophagy could be part of a protection mechanism under stress conditions. 690
The Sirt1-FoxO axis modulates autophagy in a cell-type-dependent manner in 691 response to multiple stress signals (91, 145). Thus, the role of Sirt1 in autophagy in 692 non-cardiomyocytes of the heart should be examined in the future. Moreover, other 693 transcription factors that are deacetylated by Sirt1 may also be potential targets in 694 autophagy regulation, as in the recent findings that nuclear p53 induces autophagy 695 while cytoplasmic p53 suppresses autophagy (Figure 1) (134) . protects the heart from several stresses, including ischemia/reperfusion injury, 785 hypertrophic stimuli, and oxidative injury. Stimulation of Sirt1 activity leads to 786 preservation of energy production and mitochondrial function, anti-apoptotic effects, 787 scavenging of ROS, and regulation of autophagy in the heart. Sirt3 also appears to be a 788 potential target for cardiovascular disease treatment, mainly because of its protective 789 effects upon mitochondrial function. Although Sirts4-7 also have beneficial effects in 790 cardiovascular disease, Sirt2 appears to have the opposite effect in the heart (Table) . So 791 far, Sirt1 and Sirt3 have been well-investigated and documented, and activating 792 compounds for these proteins have therapeutic potential for cardiovascular diseases 793 such as metabolic disease, ischemic heart disease, and heart failure. However, the 794 balance between the dosage of the longevity mechanism and the pathogenesis of the 795 cardiovascular disease must be carefully evaluated in order to obtain the beneficial 796 effects but eliminate the undesirable side effects of sirtuins. 
